PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SARCOMA, FIBROSARCOMA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 991 records · Page 55Linked to original sources
PubMed1986

Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy.

Soft tissue sarcomas continue to present problems with both local control of disease and death from distant metastases after accepted surgical therapy. Multimodality management has been established in the literature to be superior to traditional therapy of wide excision or amputation. The results of the treatment of 64 patients at Oregon Health Sciences University using regional hyperthermic perfusion with l-phenylalanine mustard and actinomycin D, wide local excision and external radiation therapy are reviewed. Histologic tumor types included: 19 liposarcomas, 14 malignant fibrous histiocytomas, eight fibrosarcomas, five leiomyosarcomas, four malignant schwannomas and 14 other sarcomas of the extremities. Minimum follow-up study has been 24 months and the mean follow-up time is more than five years. One-third of the patients presented with local recurrent disease after unsuccessful primary treatment. Over-all local recurrence for all patients treated by a combination of the aforementioned modalities was 3.4 per cent at two years and 11.1 per cent at five years. The over-all survival rate for all patients was 88 per cent at two years and 67 per cent at five years compared with a published over-all five year survival rate of 41 per cent. Patients with malignant fibrous histiocytomas had both two and five year local recurrence rates of 7.7 per cent and survival rates at two and five years of 79 and 63 per cent, respectively. This is compared with a previously published over-all five year survival rate with malignant fibrous histiocytomas of 46 per cent. The results with the treatment of liposarcomas were also superior to the published literature. Not only are the treatment results with regional hyperthermic perfusions excellent for both primary and locally recurrent sarcomas of the extremities, but limbs previously considered unsalvagable can be spared.

Adolescent↗
PubMed2001

Effect of modified tumor antigen on experimentally induced sarcomas.

OBJECTIVE: To explore the possibility of controlling established tumors by active immunization through specific and nonspecific methods. METHODS: By subcutaneous methylcholanthrene, a fibrosarcoma was produced in adult Swiss male mice. The fibrosarcoma was transplanted into the isogenic strain. The cleared tumor cells were injected subcutaneous into the hind leg of the 1st sarcoma group. The 2nd group received intraperitoneally sensitized spleen cells. One section of the irradiated 3rd tumor group received intraperitoneally sensitized spleen cells and subsequently a mild dose of modified tumor antigen. The 2nd section of the 3rd group was irradiated in between the administration of modified tumor antigen. In both the groups, liver of normal and transplanted tumor bearing mice was processed and intraperitoneally injected into the isogenic tumor bearing mice. Histopathology and tumor size by calipers was assessed. RESULTS: The first group showed enhancement of tumor growth in all its 3 fractions injected at different intervals. In the 2nd group, the average survival period was prolonged. In the first section of the 3rd group a decrease in tumor size and protracted survival was noted. In the transplanted tumor bearing mice, complete suppression of tumor growth was observed. In the 2nd fraction of the 3rd group, long survival period with regression of tumor was observed. In the 4th group, attenuated tumor and one mouse was observed to become tumor free after 60 days. CONCLUSION: Active immunosuppression by sensitized spleen cells and vaccines from transplanted sarcomas enabled regression of tumor size and longevity in tumor bearing mice. The modified tumor antigens, processed isogenic liver cells attenuated to zero level in tumor size in isogenic transplanted tumor bearing mice. The results show vaccines from allogenic and syngeneic sources bear the potential to regress tumor and enhance survival period.

Animals↗
PubMed1977

Kaposi's sarcoma: histopathological study of 159 cases from Malawi.

The histological features of 168 lesions of Kaposi's sarcoma from 159 patients in Malawi, where the disease is commoner than elsewhere, were characteristic. All showed well-developed areas of tumour and could be grouped fairly readily into those with a mixed pattern, a predominantly spindle cell pattern, and an anaplastic group, though intermediate patterns were seen. Hyaline bodies were present in nearly all tumours of skin. The cell of origin of Kaposi's sarcoma is uncertain and possibly has multipotential capabilities. Differential diagnosis may be difficult. Clinically the lesion may be confused with granuloma pyogenicum and may also be like it histologically. The presence of hyaline bodies and deposits of haemosiderin indicate Kaposi's sarcoma. The spindle cell predominant type may be confused with leiomyoma, leiomyosarcoma, or fibrosarcoma. The presence of hyaline bodies and the formation of vascular channels between spindle cells point to a diagnosis of Kaposi's sarcoma.

Child↗
PubMed2003

Primary nonphylloides breast sarcomas.

BACKGROUND: The prevalence of primary breast sarcoma is low, occurring in fewer than 1% of women with breast malignancies. The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms. METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001. Follow-up information was obtained. RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy. The mean patient age at presentation was 52 years (range 22 to 82). The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1). Follow-up information was available for 53 patients, with a mean follow-up of 81 months. Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease. Twenty-seven patients had no evidence of recurrence, and 3 patients were alive with disease at last follow-up. Overall median survival of patients with breast sarcoma was 58 months. Patients with angiosarcoma had a poorer outcome than other sarcoma patients. Twelve of 18 patients (67%) died of angiosarcoma, compared with 11 of 32 patients (34%) of all other sarcoma patients combined. Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy. CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor. Adjuvant chemotherapy and radiation did not improve survival in this report. Surgical extirpation remains the only effective treatment.

Adult↗
PubMed1984

Inhibitory effect of gramicidin S on the growth of murine tumor cells in vitro and in vivo.

The Effect of gramicidin S (GS), a polypeptide antibiotic, on the growth of murine tumor cells such as allotransplantable sarcoma 180 (S180) and Ehrlich ascites carcinoma (EAC) and Meth A fibrosarcoma (Meth A) was studied. GS inhibited the proliferation of EAC cells in culture and its effect on cell viability was dependent on the concentration of GS. On exposure to GS at concentrations ranging from 1 to 100 micrograms/ml for 10 min, EAC cells lost their transplantability in ddY mice depending on the concentration of GS. In particular, the transplantability of EAC cells was completely missing on exposure to GS at a concentration of 100 micrograms/ml. In the in vivo experiments, a daily intraperitoneal injection of GS exhibited a high inhibitory effect not only on the growth of subcutaneously implanted S180 in ICR mice but on the growth of subcutaneously implanted syngeneic Meth A in BALB/c mice. In the studies using radioactively labeled DNA, RNA and protein precursors, GS at high concentrations inhibited the incorporation of all the precursors into EAC cells.

Animals↗
PubMed1985

Investigations into the nature of Igh-V region-restricted T cell interactions by using antibodies to antigens on methylcholanthrene-induced sarcomas. I. Analysis of an Igh-V-restricted suppressor-inducer factor.

We have previously demonstrated the relationship between antigens on BALB/c methylcholanthrene (MC)-induced fibrosarcomas and T cell regulatory molecules by using a variety of antisera raised to these sarcomas in BALB/c and BALB/c X C57BL/6 (CB6F1) mice. One such pool of antiserum, a CB6F1 anti-CMS 4 (Pool XIV) serum, was used to investigate the nature of the T cell regulatory structures recognized by these antibodies. Pool XIV antiserum was capable of blocking the induction of feedback suppression by Ly-1 TsiF, an SRBC-specific suppressor T cell factor secreted by Ly-1+, 2- I-J+ T cells. Ly-1 TsiF induces suppression by interacting with an Ly-1+,2+ I-J+ T cell target. Successful interaction of Ly-1 TsiF with its target cell requires genetic homology between inducer and target cells at the variable region of the immunoglobulin heavy chain gene complex (Igh-V). The addition of Pool XIV antiserum to primary in vitro anti-SRBC cultures resulted in blocking the ability of Ly-1 TsiF from Igha (BALB/c) and Ighj (CBA/J) mice to induce suppression on syngeneic cells, whereas suppression induced by Ly-1 TsiF in Ighb (B6), Ighc (DBA/2), Ighd (A/J), and Ighe (AKR) mice are unaffected by addition of the Pool XIV antiserum. The ability of Pool XIV antiserum to block Ly-1 TsiF activity is linked to the Igh region, because Pool XIV antiserum can block Ly-1 TsiF from BALB/c (H-2d, Igha) and the Igh congenic B.C9 (H-2b, Igha) while not affecting Ly-1 TsiF activity on B6 (H-2b, Ighb) or its Igh congenic C.B20 (H-2d, Ighb). In CB6F1 animals, Pool XIV antiserum could block the ability of CB6F1 Ly-1 TsiF to suppress BALB/c spleen cells but not B6 spleen cells. Conversely, Pool XIV antiserum could block the ability of BALB/c Ly-1 TsiF to suppress CB6F1 spleen cells, whereas B6 Ly-1 TsiF showed normal suppressive activity in the presence of Pool XIV antiserum. In contrast, Pool XIV was capable of blocking the ability of Ly-1 TsiF from BALB/c into CB6F1 bone marrow chimeras (BMC) to suppress both BALB/c and B6 mice, whereas the activity of Ly-1 TsiF from B6 into CB6F1 BMC on BALB/c or B6 spleen cells was unaffected by the addition of Pool XIV antiserum. We then investigated the molecular nature of the molecule recognized by Pool XIV antiserum on the Ly-1 TsiF.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1988

Restoration of immune response by levamisole in B-77 virus induced tumor-bearing rats.

The immunorestorative effect of levamisole was observed in Lewis rats inoculated with a syngeneic B-77 virus induced tumor and immunized with sheep erythrocytes. In tumor-bearing rats the cell-mediated cytotoxicity, the delayed footpad reaction and the antibody production were suppressed. While the cytotoxicity suppressed in tumor-bearing rats was not restored by levamisole, delayed footpad reaction and antibody production were enhanced as compared with the normal reaction, or were restored to normal levels by levamisole, respectively. Tumor growth was significantly suppressed in rats treated with levamisole. The presence of tumor changed the uptake of 3H-uridine labeled lymphocytes in the spleen and peripheral blood. Restorative effect of levamisole on T lymphocytes was different in the studied organs.

Adjuvants, Immunologic↗
PubMed2003

A combined modality approach to recurrent cardiac sarcoma resulting in a prolonged remission: a case report.

We report a case of cardiac fibrosarcoma that was treated with cardiac tumor resection, chemotherapy, cardiac explantation, tumor repeat resection, and autotransplantation followed by external beam irradiation. The patient was able to achieve clinical remission and remained disease free > 2 years after the initial diagnosis. This case report demonstrates that a sustained remission from cardiac sarcoma is possible with an aggressive combined modality approach.

Adult↗